
Takeda has launched Orzeyful (oveporexton), the first drug to target the underlying orexin deficiency in narcolepsy type 1 (NT1). The FDA-approved treatment, classified as a Schedule IV controlled substance, is now available for adults with this rare condition. Orzeyful is an oral orexin receptor 2 agonist, specifically designed to address the orexin deficiency that drives NT1, marking a significant advancement in treatment options.
NT1, also known as narcolepsy with cataplexy, affects an estimated 120,000 people in the U.S. It results from a loss of orexin, a brain chemical that promotes wakefulness. Symptoms include excessive daytime sleepiness, cataplexy (sudden muscle weakness), cognitive issues, and disrupted nighttime sleep. This chronic neurological disease not only impacts daily functioning but also imposes a substantial financial burden on healthcare systems.
A significant breakthrough
Dr. Emmanuel Mignot, a Stanford University sleep medicine professor and lead U.S. investigator for Orzeyful’s phase 3 trials, described the drug’s arrival as “surreal.” He highlighted its unique mechanism: “Suddenly they can experience being awake as normal people.” Dr. Mignot emphasized that Orzeyful’s impact is both qualitative and quantitative, offering patients a level of wakefulness previously unattainable with existing treatments.
Dr. Mignot, who has studied orexin’s role in narcolepsy for decades, noted that Orzeyful is “qualitatively and quantitatively different” from existing treatments. While he does not view it as a “magic pill,” he believes it could replace classic stimulants for many patients, potentially in combination with sodium oxybate. He also noted that long-term effects beyond about 3 years remain unknown, showing the need for continued monitoring.
Cost and access considerations
Orzeyful’s wholesale price is set at $16,500 for a 60-tablet bottle, regardless of strength. Takeda justifies the cost, stating it reflects the drug’s innovation and value to patients, caregivers, and the healthcare system. A Takeda spokesperson emphasized that the pricing accounts for the drug’s ability to transform patients’ lives and reduce broader societal costs associated with untreated NT1.
The medication is available exclusively through Accredo Specialty Pharmacy, selected for its narcolepsy expertise and Medicaid coverage across all 50 states. Takeda’s QuickStart program assists eligible patients in starting treatment while insurance coverage is being processed. This program aims to minimize delays in accessing the medication, ensuring patients can begin therapy promptly.
Diagnosis challenges and side effects
Diagnosing NT1 remains difficult, with only about half of U.S. cases identified and an average delay of 10 years. Takeda is researching a blood-based orexin biomarker to improve detection rates. The company hopes this biomarker will streamline diagnosis, reducing the time patients spend without proper treatment.
In clinical trials, insomnia occurred in 58% of patients on Orzeyful, while urinary events affected 63%. No insomnia cases led to treatment discontinuation, though two patients stopped due to urinary symptoms. The drug is contraindicated with strong CYP3A inhibitors. Prescribers can choose between 1 mg or 2 mg doses, administered twice daily, to tailor treatment to individual patient needs.
Dr. Mignot encourages patient-clinician collaboration in treatment decisions. He notes that while trying other drugs first is often harmless, discontinuing Orzeyful could cause rebound symptoms. He stressed that the decision to use Orzeyful should be individualized, considering each patient’s unique circumstances and response to therapy.
Adults newly diagnosed with NT1 had total healthcare costs 5.5 times higher than matched controls in the first year after diagnosis, according to a Takeda-funded analysis. This highlights the economic impact of NT1 and the potential for Orzeyful to reduce long-term healthcare costs by improving symptom management and quality of life.
Takeda is not currently exploring Orzeyful for other conditions but is developing a second orexin agonist, TAK-360, for narcolepsy type 2 and idiopathic hypersomnia, with data expected by March 2027. Dr. Mignot emphasized that the success of Orzeyful could pave the way for further innovations in sleep medicine, offering hope to patients with related disorders.